Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)

NCT05163080 is registered in ClinicalTrials.gov with MimiVax, LLC as lead sponsor.

NCT NCT05163080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05163080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)
Lead sponsor
MimiVax, LLC
Phase
Phase 2
Overall status
Unknown status
Start date
November 18, 2021
Completion date
August 18, 2024
Enrollment
247 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

newly diagnosed glioblastoma